Selected article for: "SARS virus and virus contain"
Author: Anand, Uttpal; Jakhmola, Shweta; Indari, Omkar; Jha, Hem Chandra; Chen, Zhe-Sheng; Tripathi, Vijay; Pérez de la Lastra, José M.
Title: Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
  • Cord-id: lj9sjc8g
  • Document date: 2021_6_30
    • ID: lj9sjc8g
    Snippet: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID-19) worldwide. Wuhan, a city in China became the epicenter of the outbreak of COVID-19 in December 2019. The disease was declared a pandemic globally by the World Health Organization (WHO) on 11 March 2020. SARS-CoV-2 is a beta CoV of the Coronaviridae family which usually causes respiratory symptoms that resemble common cold. M
    Document: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly pathogenic novel virus that has caused a massive pandemic called coronavirus disease 2019 (COVID-19) worldwide. Wuhan, a city in China became the epicenter of the outbreak of COVID-19 in December 2019. The disease was declared a pandemic globally by the World Health Organization (WHO) on 11 March 2020. SARS-CoV-2 is a beta CoV of the Coronaviridae family which usually causes respiratory symptoms that resemble common cold. Multiple countries have experienced multiple waves of the disease and scientific experts are consistently working to find answers to several unresolved questions, with the aim to find the most suitable ways to contain the virus. Furthermore, potential therapeutic strategies and vaccine development for COVID-19 management are also considered. Currently, substantial efforts have been made to develop successful and safe treatments and SARS-CoV-2 vaccines. Some vaccines, such as inactivated vaccines, nucleic acid-based, and vector-based vaccines, have entered phase 3 clinical trials. Additionally, diverse small molecule drugs, peptides and antibodies are being developed to treat COVID-19. We present here an overview of the virus interaction with the host and environment and anti-CoV therapeutic strategies; including vaccines and other methodologies, designed for prophylaxis and treatment of SARS-CoV-2 infection with the hope that this integrative analysis could help develop novel therapeutic approaches against COVID-19.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • action mechanism and acute sars infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • action mechanism and adaptive immune response: 1, 2, 3
    • action mechanism and additional research: 1, 2, 3
    • action mechanism and adenosine analog: 1, 2
    • action mechanism and adenosine nucleotide: 1, 2
    • action mechanism and long distance: 1, 2
    • action mechanism and long protection: 1
    • action mechanism and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • action mechanism and lopinavir ritonavir favipiravir: 1, 2, 3
    • action mechanism and low specific: 1, 2
    • action mechanism and lps lipopolysaccharide: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • action mechanism and lung epithelia: 1
    • action mechanism and lung infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • action mechanism and lung microenvironment: 1
    • action mechanism and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • action mechanism and mabs monoclonal antibody: 1
    • activation viral replication and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8
    • activation viral replication and acute sars infection: 1, 2, 3